Global Pulmonary Drugs Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029
The pulmonary drugs are used for treating the conditions affecting lungs. The pulmonary drugs are used from treating minor illnesses such as the common cold to cure long-term disorders such asthma. These agents are available in different forms such as oral tablets, oral liquids, and injections or inhalations. Inhalations deliver the medicine directly to the lungs, which can act directly on the lung tissues, minimizing systemic side effects.
According to our (Global Info Research) latest study, the global Pulmonary Drugs market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The major factors driving growth of the pulmonary drugs market include increasing incidence of chronic respiratory diseases, tobacco smoking, and government and non-government initiatives.
This report is a detailed and comprehensive analysis for global Pulmonary Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Pulmonary Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Pulmonary Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Pulmonary Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Pulmonary Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Pulmonary Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Pulmonary Drugs market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZeneca Plc. and GlaxoSmithKline Plc., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Pulmonary Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Pulmonary Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Pulmonary Drugs, with price, sales, revenue and global market share of Pulmonary Drugs from 2018 to 2023.
Chapter 3, the Pulmonary Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Pulmonary Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Pulmonary Drugs market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Pulmonary Drugs.
Chapter 14 and 15, to describe Pulmonary Drugs sales channel, distributors, customers, research findings and conclusion.
According to our (Global Info Research) latest study, the global Pulmonary Drugs market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The major factors driving growth of the pulmonary drugs market include increasing incidence of chronic respiratory diseases, tobacco smoking, and government and non-government initiatives.
This report is a detailed and comprehensive analysis for global Pulmonary Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Pulmonary Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Pulmonary Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Pulmonary Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Pulmonary Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Pulmonary Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Pulmonary Drugs market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZeneca Plc. and GlaxoSmithKline Plc., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Pulmonary Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Inhaled Corticosteroids
- Long Acting Beta-2 Agonists
- Antihistamines
- Vasodilators
- Others
- Asthma & COPD
- Allergic Rhinitis
- Pulmonary Arterial Hypertension
- Cystic Fibrosis
- Others
- Sanofi SA
- Meda Pharmaceuticals
- Circassia Pharmaceuticals Plc.
- AstraZeneca Plc.
- GlaxoSmithKline Plc.
- Mallinckrodt Pharmaceuticals Plc.
- Cheisi Farmaceutici S.p.A
- Zambon Company S.p.A
- Alaxia SAS
- Merck Sharp & Dohme Limited
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Pulmonary Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Pulmonary Drugs, with price, sales, revenue and global market share of Pulmonary Drugs from 2018 to 2023.
Chapter 3, the Pulmonary Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Pulmonary Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Pulmonary Drugs market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Pulmonary Drugs.
Chapter 14 and 15, to describe Pulmonary Drugs sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Pulmonary Drugs
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Pulmonary Drugs Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Inhaled Corticosteroids
1.3.3 Long Acting Beta-2 Agonists
1.3.4 Antihistamines
1.3.5 Vasodilators
1.3.6 Others
1.4 Market Analysis by Application
1.4.1 Overview: Global Pulmonary Drugs Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Asthma & COPD
1.4.3 Allergic Rhinitis
1.4.4 Pulmonary Arterial Hypertension
1.4.5 Cystic Fibrosis
1.4.6 Others
1.5 Global Pulmonary Drugs Market Size & Forecast
1.5.1 Global Pulmonary Drugs Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Pulmonary Drugs Sales Quantity (2018-2029)
1.5.3 Global Pulmonary Drugs Average Price (2018-2029)
2 MANUFACTURERS PROFILES
2.1 Sanofi SA
2.1.1 Sanofi SA Details
2.1.2 Sanofi SA Major Business
2.1.3 Sanofi SA Pulmonary Drugs Product and Services
2.1.4 Sanofi SA Pulmonary Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Sanofi SA Recent Developments/Updates
2.2 Meda Pharmaceuticals
2.2.1 Meda Pharmaceuticals Details
2.2.2 Meda Pharmaceuticals Major Business
2.2.3 Meda Pharmaceuticals Pulmonary Drugs Product and Services
2.2.4 Meda Pharmaceuticals Pulmonary Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Meda Pharmaceuticals Recent Developments/Updates
2.3 Circassia Pharmaceuticals Plc.
2.3.1 Circassia Pharmaceuticals Plc. Details
2.3.2 Circassia Pharmaceuticals Plc. Major Business
2.3.3 Circassia Pharmaceuticals Plc. Pulmonary Drugs Product and Services
2.3.4 Circassia Pharmaceuticals Plc. Pulmonary Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Circassia Pharmaceuticals Plc. Recent Developments/Updates
2.4 AstraZeneca Plc.
2.4.1 AstraZeneca Plc. Details
2.4.2 AstraZeneca Plc. Major Business
2.4.3 AstraZeneca Plc. Pulmonary Drugs Product and Services
2.4.4 AstraZeneca Plc. Pulmonary Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 AstraZeneca Plc. Recent Developments/Updates
2.5 GlaxoSmithKline Plc.
2.5.1 GlaxoSmithKline Plc. Details
2.5.2 GlaxoSmithKline Plc. Major Business
2.5.3 GlaxoSmithKline Plc. Pulmonary Drugs Product and Services
2.5.4 GlaxoSmithKline Plc. Pulmonary Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 GlaxoSmithKline Plc. Recent Developments/Updates
2.6 Mallinckrodt Pharmaceuticals Plc.
2.6.1 Mallinckrodt Pharmaceuticals Plc. Details
2.6.2 Mallinckrodt Pharmaceuticals Plc. Major Business
2.6.3 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Product and Services
2.6.4 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Mallinckrodt Pharmaceuticals Plc. Recent Developments/Updates
2.7 Cheisi Farmaceutici S.p.A
2.7.1 Cheisi Farmaceutici S.p.A Details
2.7.2 Cheisi Farmaceutici S.p.A Major Business
2.7.3 Cheisi Farmaceutici S.p.A Pulmonary Drugs Product and Services
2.7.4 Cheisi Farmaceutici S.p.A Pulmonary Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Cheisi Farmaceutici S.p.A Recent Developments/Updates
2.8 Zambon Company S.p.A
2.8.1 Zambon Company S.p.A Details
2.8.2 Zambon Company S.p.A Major Business
2.8.3 Zambon Company S.p.A Pulmonary Drugs Product and Services
2.8.4 Zambon Company S.p.A Pulmonary Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Zambon Company S.p.A Recent Developments/Updates
2.9 Alaxia SAS
2.9.1 Alaxia SAS Details
2.9.2 Alaxia SAS Major Business
2.9.3 Alaxia SAS Pulmonary Drugs Product and Services
2.9.4 Alaxia SAS Pulmonary Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Alaxia SAS Recent Developments/Updates
2.10 Merck Sharp & Dohme Limited
2.10.1 Merck Sharp & Dohme Limited Details
2.10.2 Merck Sharp & Dohme Limited Major Business
2.10.3 Merck Sharp & Dohme Limited Pulmonary Drugs Product and Services
2.10.4 Merck Sharp & Dohme Limited Pulmonary Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Merck Sharp & Dohme Limited Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: PULMONARY DRUGS BY MANUFACTURER
3.1 Global Pulmonary Drugs Sales Quantity by Manufacturer (2018-2023)
3.2 Global Pulmonary Drugs Revenue by Manufacturer (2018-2023)
3.3 Global Pulmonary Drugs Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Pulmonary Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Pulmonary Drugs Manufacturer Market Share in 2022
3.4.2 Top 6 Pulmonary Drugs Manufacturer Market Share in 2022
3.5 Pulmonary Drugs Market: Overall Company Footprint Analysis
3.5.1 Pulmonary Drugs Market: Region Footprint
3.5.2 Pulmonary Drugs Market: Company Product Type Footprint
3.5.3 Pulmonary Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Pulmonary Drugs Market Size by Region
4.1.1 Global Pulmonary Drugs Sales Quantity by Region (2018-2029)
4.1.2 Global Pulmonary Drugs Consumption Value by Region (2018-2029)
4.1.3 Global Pulmonary Drugs Average Price by Region (2018-2029)
4.2 North America Pulmonary Drugs Consumption Value (2018-2029)
4.3 Europe Pulmonary Drugs Consumption Value (2018-2029)
4.4 Asia-Pacific Pulmonary Drugs Consumption Value (2018-2029)
4.5 South America Pulmonary Drugs Consumption Value (2018-2029)
4.6 Middle East and Africa Pulmonary Drugs Consumption Value (2018-2029)
5 MARKET SEGMENT BY TYPE
5.1 Global Pulmonary Drugs Sales Quantity by Type (2018-2029)
5.2 Global Pulmonary Drugs Consumption Value by Type (2018-2029)
5.3 Global Pulmonary Drugs Average Price by Type (2018-2029)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Pulmonary Drugs Sales Quantity by Application (2018-2029)
6.2 Global Pulmonary Drugs Consumption Value by Application (2018-2029)
6.3 Global Pulmonary Drugs Average Price by Application (2018-2029)
7 NORTH AMERICA
7.1 North America Pulmonary Drugs Sales Quantity by Type (2018-2029)
7.2 North America Pulmonary Drugs Sales Quantity by Application (2018-2029)
7.3 North America Pulmonary Drugs Market Size by Country
7.3.1 North America Pulmonary Drugs Sales Quantity by Country (2018-2029)
7.3.2 North America Pulmonary Drugs Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 EUROPE
8.1 Europe Pulmonary Drugs Sales Quantity by Type (2018-2029)
8.2 Europe Pulmonary Drugs Sales Quantity by Application (2018-2029)
8.3 Europe Pulmonary Drugs Market Size by Country
8.3.1 Europe Pulmonary Drugs Sales Quantity by Country (2018-2029)
8.3.2 Europe Pulmonary Drugs Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 ASIA-PACIFIC
9.1 Asia-Pacific Pulmonary Drugs Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Pulmonary Drugs Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Pulmonary Drugs Market Size by Region
9.3.1 Asia-Pacific Pulmonary Drugs Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Pulmonary Drugs Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 SOUTH AMERICA
10.1 South America Pulmonary Drugs Sales Quantity by Type (2018-2029)
10.2 South America Pulmonary Drugs Sales Quantity by Application (2018-2029)
10.3 South America Pulmonary Drugs Market Size by Country
10.3.1 South America Pulmonary Drugs Sales Quantity by Country (2018-2029)
10.3.2 South America Pulmonary Drugs Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Pulmonary Drugs Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Pulmonary Drugs Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Pulmonary Drugs Market Size by Country
11.3.1 Middle East & Africa Pulmonary Drugs Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Pulmonary Drugs Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 MARKET DYNAMICS
12.1 Pulmonary Drugs Market Drivers
12.2 Pulmonary Drugs Market Restraints
12.3 Pulmonary Drugs Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Pulmonary Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of Pulmonary Drugs
13.3 Pulmonary Drugs Production Process
13.4 Pulmonary Drugs Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Pulmonary Drugs Typical Distributors
14.3 Pulmonary Drugs Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope of Pulmonary Drugs
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Pulmonary Drugs Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Inhaled Corticosteroids
1.3.3 Long Acting Beta-2 Agonists
1.3.4 Antihistamines
1.3.5 Vasodilators
1.3.6 Others
1.4 Market Analysis by Application
1.4.1 Overview: Global Pulmonary Drugs Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Asthma & COPD
1.4.3 Allergic Rhinitis
1.4.4 Pulmonary Arterial Hypertension
1.4.5 Cystic Fibrosis
1.4.6 Others
1.5 Global Pulmonary Drugs Market Size & Forecast
1.5.1 Global Pulmonary Drugs Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Pulmonary Drugs Sales Quantity (2018-2029)
1.5.3 Global Pulmonary Drugs Average Price (2018-2029)
2 MANUFACTURERS PROFILES
2.1 Sanofi SA
2.1.1 Sanofi SA Details
2.1.2 Sanofi SA Major Business
2.1.3 Sanofi SA Pulmonary Drugs Product and Services
2.1.4 Sanofi SA Pulmonary Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Sanofi SA Recent Developments/Updates
2.2 Meda Pharmaceuticals
2.2.1 Meda Pharmaceuticals Details
2.2.2 Meda Pharmaceuticals Major Business
2.2.3 Meda Pharmaceuticals Pulmonary Drugs Product and Services
2.2.4 Meda Pharmaceuticals Pulmonary Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Meda Pharmaceuticals Recent Developments/Updates
2.3 Circassia Pharmaceuticals Plc.
2.3.1 Circassia Pharmaceuticals Plc. Details
2.3.2 Circassia Pharmaceuticals Plc. Major Business
2.3.3 Circassia Pharmaceuticals Plc. Pulmonary Drugs Product and Services
2.3.4 Circassia Pharmaceuticals Plc. Pulmonary Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Circassia Pharmaceuticals Plc. Recent Developments/Updates
2.4 AstraZeneca Plc.
2.4.1 AstraZeneca Plc. Details
2.4.2 AstraZeneca Plc. Major Business
2.4.3 AstraZeneca Plc. Pulmonary Drugs Product and Services
2.4.4 AstraZeneca Plc. Pulmonary Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 AstraZeneca Plc. Recent Developments/Updates
2.5 GlaxoSmithKline Plc.
2.5.1 GlaxoSmithKline Plc. Details
2.5.2 GlaxoSmithKline Plc. Major Business
2.5.3 GlaxoSmithKline Plc. Pulmonary Drugs Product and Services
2.5.4 GlaxoSmithKline Plc. Pulmonary Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 GlaxoSmithKline Plc. Recent Developments/Updates
2.6 Mallinckrodt Pharmaceuticals Plc.
2.6.1 Mallinckrodt Pharmaceuticals Plc. Details
2.6.2 Mallinckrodt Pharmaceuticals Plc. Major Business
2.6.3 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Product and Services
2.6.4 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Mallinckrodt Pharmaceuticals Plc. Recent Developments/Updates
2.7 Cheisi Farmaceutici S.p.A
2.7.1 Cheisi Farmaceutici S.p.A Details
2.7.2 Cheisi Farmaceutici S.p.A Major Business
2.7.3 Cheisi Farmaceutici S.p.A Pulmonary Drugs Product and Services
2.7.4 Cheisi Farmaceutici S.p.A Pulmonary Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Cheisi Farmaceutici S.p.A Recent Developments/Updates
2.8 Zambon Company S.p.A
2.8.1 Zambon Company S.p.A Details
2.8.2 Zambon Company S.p.A Major Business
2.8.3 Zambon Company S.p.A Pulmonary Drugs Product and Services
2.8.4 Zambon Company S.p.A Pulmonary Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Zambon Company S.p.A Recent Developments/Updates
2.9 Alaxia SAS
2.9.1 Alaxia SAS Details
2.9.2 Alaxia SAS Major Business
2.9.3 Alaxia SAS Pulmonary Drugs Product and Services
2.9.4 Alaxia SAS Pulmonary Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Alaxia SAS Recent Developments/Updates
2.10 Merck Sharp & Dohme Limited
2.10.1 Merck Sharp & Dohme Limited Details
2.10.2 Merck Sharp & Dohme Limited Major Business
2.10.3 Merck Sharp & Dohme Limited Pulmonary Drugs Product and Services
2.10.4 Merck Sharp & Dohme Limited Pulmonary Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Merck Sharp & Dohme Limited Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: PULMONARY DRUGS BY MANUFACTURER
3.1 Global Pulmonary Drugs Sales Quantity by Manufacturer (2018-2023)
3.2 Global Pulmonary Drugs Revenue by Manufacturer (2018-2023)
3.3 Global Pulmonary Drugs Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Pulmonary Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Pulmonary Drugs Manufacturer Market Share in 2022
3.4.2 Top 6 Pulmonary Drugs Manufacturer Market Share in 2022
3.5 Pulmonary Drugs Market: Overall Company Footprint Analysis
3.5.1 Pulmonary Drugs Market: Region Footprint
3.5.2 Pulmonary Drugs Market: Company Product Type Footprint
3.5.3 Pulmonary Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Pulmonary Drugs Market Size by Region
4.1.1 Global Pulmonary Drugs Sales Quantity by Region (2018-2029)
4.1.2 Global Pulmonary Drugs Consumption Value by Region (2018-2029)
4.1.3 Global Pulmonary Drugs Average Price by Region (2018-2029)
4.2 North America Pulmonary Drugs Consumption Value (2018-2029)
4.3 Europe Pulmonary Drugs Consumption Value (2018-2029)
4.4 Asia-Pacific Pulmonary Drugs Consumption Value (2018-2029)
4.5 South America Pulmonary Drugs Consumption Value (2018-2029)
4.6 Middle East and Africa Pulmonary Drugs Consumption Value (2018-2029)
5 MARKET SEGMENT BY TYPE
5.1 Global Pulmonary Drugs Sales Quantity by Type (2018-2029)
5.2 Global Pulmonary Drugs Consumption Value by Type (2018-2029)
5.3 Global Pulmonary Drugs Average Price by Type (2018-2029)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Pulmonary Drugs Sales Quantity by Application (2018-2029)
6.2 Global Pulmonary Drugs Consumption Value by Application (2018-2029)
6.3 Global Pulmonary Drugs Average Price by Application (2018-2029)
7 NORTH AMERICA
7.1 North America Pulmonary Drugs Sales Quantity by Type (2018-2029)
7.2 North America Pulmonary Drugs Sales Quantity by Application (2018-2029)
7.3 North America Pulmonary Drugs Market Size by Country
7.3.1 North America Pulmonary Drugs Sales Quantity by Country (2018-2029)
7.3.2 North America Pulmonary Drugs Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 EUROPE
8.1 Europe Pulmonary Drugs Sales Quantity by Type (2018-2029)
8.2 Europe Pulmonary Drugs Sales Quantity by Application (2018-2029)
8.3 Europe Pulmonary Drugs Market Size by Country
8.3.1 Europe Pulmonary Drugs Sales Quantity by Country (2018-2029)
8.3.2 Europe Pulmonary Drugs Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 ASIA-PACIFIC
9.1 Asia-Pacific Pulmonary Drugs Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Pulmonary Drugs Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Pulmonary Drugs Market Size by Region
9.3.1 Asia-Pacific Pulmonary Drugs Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Pulmonary Drugs Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 SOUTH AMERICA
10.1 South America Pulmonary Drugs Sales Quantity by Type (2018-2029)
10.2 South America Pulmonary Drugs Sales Quantity by Application (2018-2029)
10.3 South America Pulmonary Drugs Market Size by Country
10.3.1 South America Pulmonary Drugs Sales Quantity by Country (2018-2029)
10.3.2 South America Pulmonary Drugs Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Pulmonary Drugs Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Pulmonary Drugs Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Pulmonary Drugs Market Size by Country
11.3.1 Middle East & Africa Pulmonary Drugs Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Pulmonary Drugs Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 MARKET DYNAMICS
12.1 Pulmonary Drugs Market Drivers
12.2 Pulmonary Drugs Market Restraints
12.3 Pulmonary Drugs Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Pulmonary Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of Pulmonary Drugs
13.3 Pulmonary Drugs Production Process
13.4 Pulmonary Drugs Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Pulmonary Drugs Typical Distributors
14.3 Pulmonary Drugs Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Pulmonary Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Pulmonary Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Sanofi SA Basic Information, Manufacturing Base and Competitors
Table 4. Sanofi SA Major Business
Table 5. Sanofi SA Pulmonary Drugs Product and Services
Table 6. Sanofi SA Pulmonary Drugs Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Sanofi SA Recent Developments/Updates
Table 8. Meda Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 9. Meda Pharmaceuticals Major Business
Table 10. Meda Pharmaceuticals Pulmonary Drugs Product and Services
Table 11. Meda Pharmaceuticals Pulmonary Drugs Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Meda Pharmaceuticals Recent Developments/Updates
Table 13. Circassia Pharmaceuticals Plc. Basic Information, Manufacturing Base and Competitors
Table 14. Circassia Pharmaceuticals Plc. Major Business
Table 15. Circassia Pharmaceuticals Plc. Pulmonary Drugs Product and Services
Table 16. Circassia Pharmaceuticals Plc. Pulmonary Drugs Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Circassia Pharmaceuticals Plc. Recent Developments/Updates
Table 18. AstraZeneca Plc. Basic Information, Manufacturing Base and Competitors
Table 19. AstraZeneca Plc. Major Business
Table 20. AstraZeneca Plc. Pulmonary Drugs Product and Services
Table 21. AstraZeneca Plc. Pulmonary Drugs Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. AstraZeneca Plc. Recent Developments/Updates
Table 23. GlaxoSmithKline Plc. Basic Information, Manufacturing Base and Competitors
Table 24. GlaxoSmithKline Plc. Major Business
Table 25. GlaxoSmithKline Plc. Pulmonary Drugs Product and Services
Table 26. GlaxoSmithKline Plc. Pulmonary Drugs Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. GlaxoSmithKline Plc. Recent Developments/Updates
Table 28. Mallinckrodt Pharmaceuticals Plc. Basic Information, Manufacturing Base and Competitors
Table 29. Mallinckrodt Pharmaceuticals Plc. Major Business
Table 30. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Product and Services
Table 31. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Mallinckrodt Pharmaceuticals Plc. Recent Developments/Updates
Table 33. Cheisi Farmaceutici S.p.A Basic Information, Manufacturing Base and Competitors
Table 34. Cheisi Farmaceutici S.p.A Major Business
Table 35. Cheisi Farmaceutici S.p.A Pulmonary Drugs Product and Services
Table 36. Cheisi Farmaceutici S.p.A Pulmonary Drugs Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Cheisi Farmaceutici S.p.A Recent Developments/Updates
Table 38. Zambon Company S.p.A Basic Information, Manufacturing Base and Competitors
Table 39. Zambon Company S.p.A Major Business
Table 40. Zambon Company S.p.A Pulmonary Drugs Product and Services
Table 41. Zambon Company S.p.A Pulmonary Drugs Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Zambon Company S.p.A Recent Developments/Updates
Table 43. Alaxia SAS Basic Information, Manufacturing Base and Competitors
Table 44. Alaxia SAS Major Business
Table 45. Alaxia SAS Pulmonary Drugs Product and Services
Table 46. Alaxia SAS Pulmonary Drugs Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Alaxia SAS Recent Developments/Updates
Table 48. Merck Sharp & Dohme Limited Basic Information, Manufacturing Base and Competitors
Table 49. Merck Sharp & Dohme Limited Major Business
Table 50. Merck Sharp & Dohme Limited Pulmonary Drugs Product and Services
Table 51. Merck Sharp & Dohme Limited Pulmonary Drugs Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Merck Sharp & Dohme Limited Recent Developments/Updates
Table 53. Global Pulmonary Drugs Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 54. Global Pulmonary Drugs Revenue by Manufacturer (2018-2023) & (USD Million)
Table 55. Global Pulmonary Drugs Average Price by Manufacturer (2018-2023) & (USD/Unit)
Table 56. Market Position of Manufacturers in Pulmonary Drugs, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 57. Head Office and Pulmonary Drugs Production Site of Key Manufacturer
Table 58. Pulmonary Drugs Market: Company Product Type Footprint
Table 59. Pulmonary Drugs Market: Company Product Application Footprint
Table 60. Pulmonary Drugs New Market Entrants and Barriers to Market Entry
Table 61. Pulmonary Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 62. Global Pulmonary Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 63. Global Pulmonary Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 64. Global Pulmonary Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 65. Global Pulmonary Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 66. Global Pulmonary Drugs Average Price by Region (2018-2023) & (USD/Unit)
Table 67. Global Pulmonary Drugs Average Price by Region (2024-2029) & (USD/Unit)
Table 68. Global Pulmonary Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 69. Global Pulmonary Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 70. Global Pulmonary Drugs Consumption Value by Type (2018-2023) & (USD Million)
Table 71. Global Pulmonary Drugs Consumption Value by Type (2024-2029) & (USD Million)
Table 72. Global Pulmonary Drugs Average Price by Type (2018-2023) & (USD/Unit)
Table 73. Global Pulmonary Drugs Average Price by Type (2024-2029) & (USD/Unit)
Table 74. Global Pulmonary Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 75. Global Pulmonary Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 76. Global Pulmonary Drugs Consumption Value by Application (2018-2023) & (USD Million)
Table 77. Global Pulmonary Drugs Consumption Value by Application (2024-2029) & (USD Million)
Table 78. Global Pulmonary Drugs Average Price by Application (2018-2023) & (USD/Unit)
Table 79. Global Pulmonary Drugs Average Price by Application (2024-2029) & (USD/Unit)
Table 80. North America Pulmonary Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 81. North America Pulmonary Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 82. North America Pulmonary Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 83. North America Pulmonary Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 84. North America Pulmonary Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 85. North America Pulmonary Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 86. North America Pulmonary Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 87. North America Pulmonary Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 88. Europe Pulmonary Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 89. Europe Pulmonary Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 90. Europe Pulmonary Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 91. Europe Pulmonary Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 92. Europe Pulmonary Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 93. Europe Pulmonary Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 94. Europe Pulmonary Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 95. Europe Pulmonary Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 96. Asia-Pacific Pulmonary Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 97. Asia-Pacific Pulmonary Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 98. Asia-Pacific Pulmonary Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 99. Asia-Pacific Pulmonary Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 100. Asia-Pacific Pulmonary Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 101. Asia-Pacific Pulmonary Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 102. Asia-Pacific Pulmonary Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 103. Asia-Pacific Pulmonary Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 104. South America Pulmonary Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 105. South America Pulmonary Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 106. South America Pulmonary Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 107. South America Pulmonary Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 108. South America Pulmonary Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 109. South America Pulmonary Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 110. South America Pulmonary Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 111. South America Pulmonary Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 112. Middle East & Africa Pulmonary Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 113. Middle East & Africa Pulmonary Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 114. Middle East & Africa Pulmonary Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 115. Middle East & Africa Pulmonary Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 116. Middle East & Africa Pulmonary Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 117. Middle East & Africa Pulmonary Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 118. Middle East & Africa Pulmonary Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 119. Middle East & Africa Pulmonary Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 120. Pulmonary Drugs Raw Material
Table 121. Key Manufacturers of Pulmonary Drugs Raw Materials
Table 122. Pulmonary Drugs Typical Distributors
Table 123. Pulmonary Drugs Typical Customers
Table 1. Global Pulmonary Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Pulmonary Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Sanofi SA Basic Information, Manufacturing Base and Competitors
Table 4. Sanofi SA Major Business
Table 5. Sanofi SA Pulmonary Drugs Product and Services
Table 6. Sanofi SA Pulmonary Drugs Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Sanofi SA Recent Developments/Updates
Table 8. Meda Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 9. Meda Pharmaceuticals Major Business
Table 10. Meda Pharmaceuticals Pulmonary Drugs Product and Services
Table 11. Meda Pharmaceuticals Pulmonary Drugs Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Meda Pharmaceuticals Recent Developments/Updates
Table 13. Circassia Pharmaceuticals Plc. Basic Information, Manufacturing Base and Competitors
Table 14. Circassia Pharmaceuticals Plc. Major Business
Table 15. Circassia Pharmaceuticals Plc. Pulmonary Drugs Product and Services
Table 16. Circassia Pharmaceuticals Plc. Pulmonary Drugs Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Circassia Pharmaceuticals Plc. Recent Developments/Updates
Table 18. AstraZeneca Plc. Basic Information, Manufacturing Base and Competitors
Table 19. AstraZeneca Plc. Major Business
Table 20. AstraZeneca Plc. Pulmonary Drugs Product and Services
Table 21. AstraZeneca Plc. Pulmonary Drugs Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. AstraZeneca Plc. Recent Developments/Updates
Table 23. GlaxoSmithKline Plc. Basic Information, Manufacturing Base and Competitors
Table 24. GlaxoSmithKline Plc. Major Business
Table 25. GlaxoSmithKline Plc. Pulmonary Drugs Product and Services
Table 26. GlaxoSmithKline Plc. Pulmonary Drugs Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. GlaxoSmithKline Plc. Recent Developments/Updates
Table 28. Mallinckrodt Pharmaceuticals Plc. Basic Information, Manufacturing Base and Competitors
Table 29. Mallinckrodt Pharmaceuticals Plc. Major Business
Table 30. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Product and Services
Table 31. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Mallinckrodt Pharmaceuticals Plc. Recent Developments/Updates
Table 33. Cheisi Farmaceutici S.p.A Basic Information, Manufacturing Base and Competitors
Table 34. Cheisi Farmaceutici S.p.A Major Business
Table 35. Cheisi Farmaceutici S.p.A Pulmonary Drugs Product and Services
Table 36. Cheisi Farmaceutici S.p.A Pulmonary Drugs Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Cheisi Farmaceutici S.p.A Recent Developments/Updates
Table 38. Zambon Company S.p.A Basic Information, Manufacturing Base and Competitors
Table 39. Zambon Company S.p.A Major Business
Table 40. Zambon Company S.p.A Pulmonary Drugs Product and Services
Table 41. Zambon Company S.p.A Pulmonary Drugs Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Zambon Company S.p.A Recent Developments/Updates
Table 43. Alaxia SAS Basic Information, Manufacturing Base and Competitors
Table 44. Alaxia SAS Major Business
Table 45. Alaxia SAS Pulmonary Drugs Product and Services
Table 46. Alaxia SAS Pulmonary Drugs Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Alaxia SAS Recent Developments/Updates
Table 48. Merck Sharp & Dohme Limited Basic Information, Manufacturing Base and Competitors
Table 49. Merck Sharp & Dohme Limited Major Business
Table 50. Merck Sharp & Dohme Limited Pulmonary Drugs Product and Services
Table 51. Merck Sharp & Dohme Limited Pulmonary Drugs Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Merck Sharp & Dohme Limited Recent Developments/Updates
Table 53. Global Pulmonary Drugs Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 54. Global Pulmonary Drugs Revenue by Manufacturer (2018-2023) & (USD Million)
Table 55. Global Pulmonary Drugs Average Price by Manufacturer (2018-2023) & (USD/Unit)
Table 56. Market Position of Manufacturers in Pulmonary Drugs, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 57. Head Office and Pulmonary Drugs Production Site of Key Manufacturer
Table 58. Pulmonary Drugs Market: Company Product Type Footprint
Table 59. Pulmonary Drugs Market: Company Product Application Footprint
Table 60. Pulmonary Drugs New Market Entrants and Barriers to Market Entry
Table 61. Pulmonary Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 62. Global Pulmonary Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 63. Global Pulmonary Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 64. Global Pulmonary Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 65. Global Pulmonary Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 66. Global Pulmonary Drugs Average Price by Region (2018-2023) & (USD/Unit)
Table 67. Global Pulmonary Drugs Average Price by Region (2024-2029) & (USD/Unit)
Table 68. Global Pulmonary Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 69. Global Pulmonary Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 70. Global Pulmonary Drugs Consumption Value by Type (2018-2023) & (USD Million)
Table 71. Global Pulmonary Drugs Consumption Value by Type (2024-2029) & (USD Million)
Table 72. Global Pulmonary Drugs Average Price by Type (2018-2023) & (USD/Unit)
Table 73. Global Pulmonary Drugs Average Price by Type (2024-2029) & (USD/Unit)
Table 74. Global Pulmonary Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 75. Global Pulmonary Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 76. Global Pulmonary Drugs Consumption Value by Application (2018-2023) & (USD Million)
Table 77. Global Pulmonary Drugs Consumption Value by Application (2024-2029) & (USD Million)
Table 78. Global Pulmonary Drugs Average Price by Application (2018-2023) & (USD/Unit)
Table 79. Global Pulmonary Drugs Average Price by Application (2024-2029) & (USD/Unit)
Table 80. North America Pulmonary Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 81. North America Pulmonary Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 82. North America Pulmonary Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 83. North America Pulmonary Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 84. North America Pulmonary Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 85. North America Pulmonary Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 86. North America Pulmonary Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 87. North America Pulmonary Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 88. Europe Pulmonary Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 89. Europe Pulmonary Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 90. Europe Pulmonary Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 91. Europe Pulmonary Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 92. Europe Pulmonary Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 93. Europe Pulmonary Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 94. Europe Pulmonary Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 95. Europe Pulmonary Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 96. Asia-Pacific Pulmonary Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 97. Asia-Pacific Pulmonary Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 98. Asia-Pacific Pulmonary Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 99. Asia-Pacific Pulmonary Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 100. Asia-Pacific Pulmonary Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 101. Asia-Pacific Pulmonary Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 102. Asia-Pacific Pulmonary Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 103. Asia-Pacific Pulmonary Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 104. South America Pulmonary Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 105. South America Pulmonary Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 106. South America Pulmonary Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 107. South America Pulmonary Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 108. South America Pulmonary Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 109. South America Pulmonary Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 110. South America Pulmonary Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 111. South America Pulmonary Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 112. Middle East & Africa Pulmonary Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 113. Middle East & Africa Pulmonary Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 114. Middle East & Africa Pulmonary Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 115. Middle East & Africa Pulmonary Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 116. Middle East & Africa Pulmonary Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 117. Middle East & Africa Pulmonary Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 118. Middle East & Africa Pulmonary Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 119. Middle East & Africa Pulmonary Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 120. Pulmonary Drugs Raw Material
Table 121. Key Manufacturers of Pulmonary Drugs Raw Materials
Table 122. Pulmonary Drugs Typical Distributors
Table 123. Pulmonary Drugs Typical Customers
LIST OF FIGURES
Figure 1. Pulmonary Drugs Picture
Figure 2. Global Pulmonary Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Pulmonary Drugs Consumption Value Market Share by Type in 2022
Figure 4. Inhaled Corticosteroids Examples
Figure 5. Long Acting Beta-2 Agonists Examples
Figure 6. Antihistamines Examples
Figure 7. Vasodilators Examples
Figure 8. Others Examples
Figure 9. Global Pulmonary Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 10. Global Pulmonary Drugs Consumption Value Market Share by Application in 2022
Figure 11. Asthma & COPD Examples
Figure 12. Allergic Rhinitis Examples
Figure 13. Pulmonary Arterial Hypertension Examples
Figure 14. Cystic Fibrosis Examples
Figure 15. Others Examples
Figure 16. Global Pulmonary Drugs Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 17. Global Pulmonary Drugs Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 18. Global Pulmonary Drugs Sales Quantity (2018-2029) & (K Units)
Figure 19. Global Pulmonary Drugs Average Price (2018-2029) & (USD/Unit)
Figure 20. Global Pulmonary Drugs Sales Quantity Market Share by Manufacturer in 2022
Figure 21. Global Pulmonary Drugs Consumption Value Market Share by Manufacturer in 2022
Figure 22. Producer Shipments of Pulmonary Drugs by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 23. Top 3 Pulmonary Drugs Manufacturer (Consumption Value) Market Share in 2022
Figure 24. Top 6 Pulmonary Drugs Manufacturer (Consumption Value) Market Share in 2022
Figure 25. Global Pulmonary Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 26. Global Pulmonary Drugs Consumption Value Market Share by Region (2018-2029)
Figure 27. North America Pulmonary Drugs Consumption Value (2018-2029) & (USD Million)
Figure 28. Europe Pulmonary Drugs Consumption Value (2018-2029) & (USD Million)
Figure 29. Asia-Pacific Pulmonary Drugs Consumption Value (2018-2029) & (USD Million)
Figure 30. South America Pulmonary Drugs Consumption Value (2018-2029) & (USD Million)
Figure 31. Middle East & Africa Pulmonary Drugs Consumption Value (2018-2029) & (USD Million)
Figure 32. Global Pulmonary Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 33. Global Pulmonary Drugs Consumption Value Market Share by Type (2018-2029)
Figure 34. Global Pulmonary Drugs Average Price by Type (2018-2029) & (USD/Unit)
Figure 35. Global Pulmonary Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 36. Global Pulmonary Drugs Consumption Value Market Share by Application (2018-2029)
Figure 37. Global Pulmonary Drugs Average Price by Application (2018-2029) & (USD/Unit)
Figure 38. North America Pulmonary Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 39. North America Pulmonary Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 40. North America Pulmonary Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 41. North America Pulmonary Drugs Consumption Value Market Share by Country (2018-2029)
Figure 42. United States Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 43. Canada Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 44. Mexico Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. Europe Pulmonary Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 46. Europe Pulmonary Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 47. Europe Pulmonary Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 48. Europe Pulmonary Drugs Consumption Value Market Share by Country (2018-2029)
Figure 49. Germany Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. France Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. United Kingdom Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 52. Russia Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 53. Italy Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Asia-Pacific Pulmonary Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 55. Asia-Pacific Pulmonary Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 56. Asia-Pacific Pulmonary Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 57. Asia-Pacific Pulmonary Drugs Consumption Value Market Share by Region (2018-2029)
Figure 58. China Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Japan Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. Korea Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. India Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 62. Southeast Asia Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 63. Australia Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. South America Pulmonary Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 65. South America Pulmonary Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 66. South America Pulmonary Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 67. South America Pulmonary Drugs Consumption Value Market Share by Country (2018-2029)
Figure 68. Brazil Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 69. Argentina Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Middle East & Africa Pulmonary Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 71. Middle East & Africa Pulmonary Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 72. Middle East & Africa Pulmonary Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 73. Middle East & Africa Pulmonary Drugs Consumption Value Market Share by Region (2018-2029)
Figure 74. Turkey Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. Egypt Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 76. Saudi Arabia Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 77. South Africa Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 78. Pulmonary Drugs Market Drivers
Figure 79. Pulmonary Drugs Market Restraints
Figure 80. Pulmonary Drugs Market Trends
Figure 81. Porters Five Forces Analysis
Figure 82. Manufacturing Cost Structure Analysis of Pulmonary Drugs in 2022
Figure 83. Manufacturing Process Analysis of Pulmonary Drugs
Figure 84. Pulmonary Drugs Industrial Chain
Figure 85. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 86. Direct Channel Pros & Cons
Figure 87. Indirect Channel Pros & Cons
Figure 88. Methodology
Figure 89. Research Process and Data Source
Figure 1. Pulmonary Drugs Picture
Figure 2. Global Pulmonary Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Pulmonary Drugs Consumption Value Market Share by Type in 2022
Figure 4. Inhaled Corticosteroids Examples
Figure 5. Long Acting Beta-2 Agonists Examples
Figure 6. Antihistamines Examples
Figure 7. Vasodilators Examples
Figure 8. Others Examples
Figure 9. Global Pulmonary Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 10. Global Pulmonary Drugs Consumption Value Market Share by Application in 2022
Figure 11. Asthma & COPD Examples
Figure 12. Allergic Rhinitis Examples
Figure 13. Pulmonary Arterial Hypertension Examples
Figure 14. Cystic Fibrosis Examples
Figure 15. Others Examples
Figure 16. Global Pulmonary Drugs Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 17. Global Pulmonary Drugs Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 18. Global Pulmonary Drugs Sales Quantity (2018-2029) & (K Units)
Figure 19. Global Pulmonary Drugs Average Price (2018-2029) & (USD/Unit)
Figure 20. Global Pulmonary Drugs Sales Quantity Market Share by Manufacturer in 2022
Figure 21. Global Pulmonary Drugs Consumption Value Market Share by Manufacturer in 2022
Figure 22. Producer Shipments of Pulmonary Drugs by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 23. Top 3 Pulmonary Drugs Manufacturer (Consumption Value) Market Share in 2022
Figure 24. Top 6 Pulmonary Drugs Manufacturer (Consumption Value) Market Share in 2022
Figure 25. Global Pulmonary Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 26. Global Pulmonary Drugs Consumption Value Market Share by Region (2018-2029)
Figure 27. North America Pulmonary Drugs Consumption Value (2018-2029) & (USD Million)
Figure 28. Europe Pulmonary Drugs Consumption Value (2018-2029) & (USD Million)
Figure 29. Asia-Pacific Pulmonary Drugs Consumption Value (2018-2029) & (USD Million)
Figure 30. South America Pulmonary Drugs Consumption Value (2018-2029) & (USD Million)
Figure 31. Middle East & Africa Pulmonary Drugs Consumption Value (2018-2029) & (USD Million)
Figure 32. Global Pulmonary Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 33. Global Pulmonary Drugs Consumption Value Market Share by Type (2018-2029)
Figure 34. Global Pulmonary Drugs Average Price by Type (2018-2029) & (USD/Unit)
Figure 35. Global Pulmonary Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 36. Global Pulmonary Drugs Consumption Value Market Share by Application (2018-2029)
Figure 37. Global Pulmonary Drugs Average Price by Application (2018-2029) & (USD/Unit)
Figure 38. North America Pulmonary Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 39. North America Pulmonary Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 40. North America Pulmonary Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 41. North America Pulmonary Drugs Consumption Value Market Share by Country (2018-2029)
Figure 42. United States Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 43. Canada Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 44. Mexico Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. Europe Pulmonary Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 46. Europe Pulmonary Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 47. Europe Pulmonary Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 48. Europe Pulmonary Drugs Consumption Value Market Share by Country (2018-2029)
Figure 49. Germany Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. France Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. United Kingdom Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 52. Russia Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 53. Italy Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Asia-Pacific Pulmonary Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 55. Asia-Pacific Pulmonary Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 56. Asia-Pacific Pulmonary Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 57. Asia-Pacific Pulmonary Drugs Consumption Value Market Share by Region (2018-2029)
Figure 58. China Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Japan Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. Korea Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. India Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 62. Southeast Asia Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 63. Australia Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. South America Pulmonary Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 65. South America Pulmonary Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 66. South America Pulmonary Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 67. South America Pulmonary Drugs Consumption Value Market Share by Country (2018-2029)
Figure 68. Brazil Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 69. Argentina Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Middle East & Africa Pulmonary Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 71. Middle East & Africa Pulmonary Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 72. Middle East & Africa Pulmonary Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 73. Middle East & Africa Pulmonary Drugs Consumption Value Market Share by Region (2018-2029)
Figure 74. Turkey Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. Egypt Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 76. Saudi Arabia Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 77. South Africa Pulmonary Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 78. Pulmonary Drugs Market Drivers
Figure 79. Pulmonary Drugs Market Restraints
Figure 80. Pulmonary Drugs Market Trends
Figure 81. Porters Five Forces Analysis
Figure 82. Manufacturing Cost Structure Analysis of Pulmonary Drugs in 2022
Figure 83. Manufacturing Process Analysis of Pulmonary Drugs
Figure 84. Pulmonary Drugs Industrial Chain
Figure 85. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 86. Direct Channel Pros & Cons
Figure 87. Indirect Channel Pros & Cons
Figure 88. Methodology
Figure 89. Research Process and Data Source
